As of Friday close, Revance Therapeutics Inc.’s (NASDAQ:RVNC) stock was up $0.54, moving up 4.33 percent to $13.01. The average number of shares traded per day over the past five days has been 5,564,840 shares. 1 time new highs have been achieved over the past 5 days, with a -$3.79 fall in that time frame. In the last twenty days, the average volume was 2,496,445, while in the previous 50 days, it was 1,857,420.
Since last month, RVNC stock retreated -30.09%. Shares of the company fell to $11.10 on 09/19/23, the lowest level in the past month. A 52-week high of $37.98 was reached on 05/09/23 after having rallying from a 52-week low of $11.10. Since the beginning of this year, RVNC’s stock price has dropped by -29.52% or -$5.45, and marked a new high 13 times. However, the stock has declined by -65.75% since its 52-week high.
RVNC stock investors should be aware that Revance Therapeutics Inc. (RVNC) stock had its last reported insider trading activity 17 days ago on Sep 06. Moxie Dwight, the SVP, GC & Secretary of the company, disposed of 11,000 shares for $17.06 on Sep 06. It resulted in a $187,704 divestment by the insider. Moxie Dwight sold 23,853 shares at an average price of $17.81 on Sep 05. The insider now owns 55,066 shares following the transaction. On Aug 03, CEO Foley Mark J sold 26,279 shares at $22.57 apiece. The transaction was valued at $593,151.
Valuation Metrics
The stock’s beta is 0.87. Besides these, the trailing price-to-sales (P/S) ratio of 6.30, the price-to-book (PB) ratio of 40.66.
Financial Health
In the three months ended June 29, Revance Therapeutics Inc.’s quick ratio stood at 4.70, while its current ratio was 5.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 14.19, and the total debt-to-equity ratio was 14.77. On the profitability front, the trailing twelve-month gross margin is 61.50% percent. Based on annual data, RVNC earned $80.9 million in gross profit and brought in $132.56 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -87.30%. Return on equity (ROE) for the past 12 months was -903.30%.
In Revance Therapeutics Inc.’s quarter-end financial report for June 29, it reported total debt of $380.35 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. RVNC’s revenue rose 51.2% to $49.33 million during the quarter, while net income inched up to $58.13 million. While analysts expected Revance Therapeutics Inc. to report -$0.78 quarterly earnings, the actual figure was -$0.8 per share, beating the consensus estimate by -2.60%. During the quarter, the company generated -$62.9 million in EBITDA. The liabilities of Revance Therapeutics Inc. were 570.75 million at the end of its most recent quarter ended June 29, and its total debt was $432.39 million. The value of shareholders’ equity is $87.95 million.
Technical Picture
This quick technical analysis looks at Revance Therapeutics Inc.’s (RVNC) price momentum. With a historical volatility rate of 112.02%, the RSI 9-day stood at 25.69% on 22 September.
With respect to its five-day moving average, the current Revance Therapeutics Inc. price is down by -22.56% percent or -$3.79. At present, RVNC shares trade -29.90% below its 20-day simple moving average and -59.71% percent below its 100-day simple moving average. However, the stock is currently trading approximately -43.99% below its SMA50 and -38.34% below its SMA200.
Stochastic coefficient K was 24.68% and Stochastic coefficient D was 29.99%, while ATR was 1.27. Given the Stochastic reading of 26.86% for the 14-day period, the RSI (14) reading has been calculated as 27.20%. As of today, the MACD Oscillator reading stands at -2.27, while the 14-day reading stands at -2.71.
